Epigenetic biomarker composition for diagnosing down syndrome, and use thereof
By measuring genetic methylation levels of specific genes, the method addresses the limitations of existing Down syndrome diagnosis technologies, offering a cost-effective and accessible solution for diagnosing Down syndrome.
Patent Information
- Application Number
- JP2024112087
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-07-02
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-06
AI Technical Summary
Existing methods for diagnosing Down syndrome, such as NGS-based NIPT and SNP-based NIPT, require expensive equipment and complex analysis, limiting their accessibility and accuracy in general laboratories, and there is a lack of clear accuracy benchmarks.
A method involving the measurement of genetic methylation levels of specific genes, including MXRA8, MIB2, KIF26B, SP5, ZIC4, and others, to diagnose Down syndrome without the need for expensive testing equipment or special algorithms, using methylation-specific PCR and other methylation level measurement techniques.
Enables simple and accurate diagnosis of Down syndrome by measuring methylation levels of biomarker genes, providing a cost-effective and accessible solution for laboratories.
Smart Images

Figure 2024156700000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a biomarker composition for diagnosing Down's syndrome and uses thereof. [Background technology]
[0002] Mutations due to structural chromosomal abnormalities result in abnormal development and death of the embryo. However, in the case of Down's syndrome (DS), one of the most common genetic causes of developmental disabilities, the embryo survives. According to the World Health Organization (WHO), the incidence of Down's syndrome, the most common genetic cause of developmental disabilities, ranges from approximately 1 to 100 out of 1,100 cases worldwide. Down's syndrome presents with over 80 clinical features, including mental retardation, facial anatomy, poor muscle development, and short stature, and is associated with an increased risk of congenital heart disease, diabetes, leukemia, and other diseases.
[0003] Conventionally, there is a method for diagnosing Down's syndrome (NGS-based NIPT) that analyzes the quantitative difference of cfDNA, which is a non-cellular DNA fragment present in the plasma of pregnant women. This method has shown high detection accuracy for Down's syndrome and has been applied to clinical practice early on. However, it requires expensive equipment and test consumables, and the analysis method is complicated, making it difficult to apply in general laboratories, and the high cost of testing makes it difficult to apply to all pregnant women. There is also a method that uses SNPs (PCR-based NIPT), but it has no clear basis for the accuracy of the test and requires the use of special algorithms presented by each institution, so it is limited in its general use. In other words, research on analysis methods that can know in advance whether a patient has a disease through genetic analysis for the above-mentioned chromosomal abnormality diseases is being actively conducted (Korean Patent Publication No. 10-2019-0003987), but it is not yet sufficient.
[0004] Under such circumstances, the present inventors have completed the present invention, which can effectively test for Down's syndrome through a simple measurement of the methylation level of genes, without the need to utilize existing expensive testing equipment or special algorithms. Summary of the Invention [Problem to be solved by the invention]
[0005] In one embodiment, the nucleotide sequences of MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ32255, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, LOC101928483, EGFL7, NACC2, C9orf69, TLX1, FGF8, TACC2, CPXM2, NKX6-2, TLX1NB, IQSEC3, PCDH8, F7, SOX9, PNMAL2, THBD, MAPK8IP2, KLHDC7B, GPR143, IGHMBP The present invention provides a composition for diagnosing Down's syndrome, comprising a preparation for measuring the methylation level of any one gene selected from the group consisting of 2, MRGPRD, CHODL, NCAM2, CYYR1, GRIK1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, C21orf2, TRPM2, TSPEAR, LINC00162, SSR4P1, SLC19A1, LOC100129027, MCM3AP, YBEY, PRMT2 and ITSN1.
[0006] Another aspect provides a kit for diagnosing Down's syndrome comprising the composition.
[0007] Yet another embodiment is directed to (a) detecting from a biological sample isolated from a fetus, among others, MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ32255, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, LOC101928483, EGFL7, NACC2, C9orf69, TLX1, FGF8, TACC2, CPXM2, NKX6-2, TLX1NB, IQSEC3, PCDH8, F7, SOX9, PNMAL2, THBD, MAPK8IP2, KLHDC7B, GPR143, IGHMBP2, MRGPRD, CHODL, NCAM, or the like. and (b) measuring the methylation level of any one gene selected from the group consisting of: CYYR1, GRIK1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, C21orf2, TRPM2, TSPEAR, LINC00162, SSR4P1, SLC19A1, LOC100129027, MCM3AP, YBEY, PRMT2, and ITSN1; and (b) comparing the measured methylation level with that of a normal control sample. [Means for solving the problem]
[0008] In one embodiment, the antibodies are selected from the group consisting of MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ32255, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, LOC101928483, EGFL7, NACC2, C9orf69, TLX1, FGF8, TACC2, CPXM2, NKX6-2, TLX1NB, IQSEC3, PCDH8, F7, SOX9, PNMAL2, THBD, MAPK8IP2, KLHDC7B, GPR143, IGHMBP2, MR The present invention provides a composition for diagnosing Down's syndrome, comprising a preparation for measuring the methylation level of any one gene selected from the group consisting of GPRD, CHODL, NCAM2, CYYR1, GRIK1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, C21orf2, TRPM2, TSPEAR, LINC00162, SSR4P1, SLC19A1, LOC100129027, MCM3AP, YBEY, PRMT2 and ITSN1.
[0009] The term "Down's syndrome" in this specification means a type of congenital genetic disease, which is manifested by the presence of an extra copy of chromosome 21, either in part or in its entirety, compared to the normal level. Down's syndrome can cause delayed physical development and can be accompanied by facial deformities and intellectual disability. The chromosomes of parents with Down's syndrome are almost normal, but an extra copy of chromosome 21 is present during pregnancy due to non-disjunction of germ cells. The incidence rate is 0.1% in women aged 20, but increases sharply to 4% in women aged 45, showing that the incidence rate increases with the age of the mother. Down's syndrome can be confirmed during pregnancy through prenatal diagnosis of the fetus, and can also be identified through direct genetic testing after birth.
[0010] As used herein, the term "diagnosis" refers to determining the presence or characteristics of a pathological condition, and also includes determining whether or not a person has Down's Syndrome or is likely to have the condition.
[0011] As used herein, the term "methylation" refers to the addition of a methyl group to the fifth carbon of a cytosine residue in DNA, and may refer to the attachment of a methyl group to a base that constitutes DNA.
[0012] Preferably, the methylation level refers to the methylation level at the fifth carbon of the cytosine residue at a specific CpG site of a specific gene. When the methylation level occurs, the binding of a transcription factor is hindered, and the expression of the specific gene is suppressed, whereas when the methylation level is non-methylated or hypomethylated, the expression of the specific gene is increased. In addition to A, C, G, and T, the genomic DNA of mammalian cells contains a fifth base called 5-methylcytosine (5-mC (5-methylcytosine)) in which a methyl group is attached to the fifth carbon of the cytosine ring. Methylation of 5-methylcytosine mainly occurs at the C of CG dinucleotide (5'-mCG-3') called CpG, and methylation of CpG suppresses the expression of a repeated sequence between alu or transposon and genome. Additionally, CpGs are the sites at which most epigenetic changes occur in mammalian cells because the 5-mC of the CpG is prone to spontaneous deamination to thymine (T).
[0013] The term "methylation level measurement" in the present specification also includes measuring the degree of methylation level of a Down's syndrome-related gene biomarker in a biological sample to diagnose Down's syndrome. The methylation level measurement is a measurement of the methylation level of a CpG site, and any known method for measuring methylation levels in the art can be used without limitation, and can be measured through methylation-specific PCR, for example, methylation-specific PCR (MSP (methylation-specific polymerase chain reaction), real-time methylation-specific polymerase chain reaction), PCR using a methylated DNA specific binding protein, quantitative PCR, PCR using a methylation-specific PNA, or melting curve analysis. Alternatively, it can be measured by a method such as an automated base analysis method, such as a DNA chip, pyrosequencing, bisulfite sequencing, and methylation next-generation base sequence sequencing (MC-Seq (methyl-capture sequencing)), but is not limited thereto.
[0014] The term "DMC (differentially methylated CpG site)" in this specification may refer to a CpG site that shows different DNA methylation status depending on the developmental stage, tissue type, and the presence or absence of disease. A region in a gene where the DMC is repeatedly present may be called a "DMR (differentially methylated CpG region)". Most DNA methylation occurs at CpG positions, where C represents cytosine, G represents guanine, and p represents a phosphodiester bond between cytosine and guanine. In somatic cells of healthy individuals, CpG islands in housekeeping gene promoter sites are unmethylated, and genes that are not expressed during the developmental process, such as imprinted genes and genes on the X chromosome in an inactive state, are methylated.
[0015] The preparation for measuring the methylation level is a preparation for confirming the presence or absence of methylation of a gene, and is also for measuring the amount of a methylated gene. For example, the preparation for measuring the methylation level may include a compound that modifies an unmethylated cytosine base, or a methylation-specific restriction enzyme (MSRE), a primer specific to a methylated sequence of the gene, and a primer specific to an unmethylated sequence. The compound that modifies an unmethylated cytosine base may be, but is not limited to, bisulfite, and is preferably sodium bisulfite. A method for detecting the methylation of a promoter by modifying an unmethylated cytosine residue using such bisulfite is well known in the art. The methylation-specific restriction enzyme refers to an enzyme that selectively cuts a nucleic acid depending on the methylation state of its restriction site. In the case of a restriction enzyme that specifically cuts when the restriction site is unmethylated or semi-methylated, if the restriction site is methylated, cutting will not occur or will occur with a significantly reduced efficiency. In the case of a restriction enzyme that cuts specifically when the restriction site is methylated, cleavage will not occur, or will occur with greatly reduced efficiency, if the restriction site is not methylated.
[0016] The aforementioned MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ32255, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, LOC101928483, EGFL7, NACC2, C9orf69, TLX1, FGF8, TACC2, CPXM2, NKX6-2, TLX1NB, IQSEC3, PCDH8, F7, SOX9, PNMAL2, THBD, MAPK8IP2, KLHDC7B, GPR143, IGHMBP2 and MRGPRD genes are also present on other chromosomes except chromosome 21.
[0017] The aforementioned CHODL, NCAM2, CYYR1, GRIK1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, C21orf2, TRPM2, TSPEAR, LINC00162, SSR4P1, SLC19A1, LOC100129027, MCM3AP, YBEY, PRMT2 and ITSN1 genes are also present on chromosome 21.
[0018] The aforementioned MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ32255, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, LOC101928483 , EGFL7, NACC2, C9orf69, TLX1, FGF8, TACC2, CPXM2, NKX6-2, TLX1NB, IQSEC3, PCDH8, F7, SOX9, PNMAL2, THBD, MAPK8IP2, KLHDC7B, GPR143, CHODL, NCAM2 The methylation level of any one of the genes selected from the group consisting of CYYR1, GRIK1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, C21orf2, TRPM2, TSPEAR, LINC00162, SSR4P1, SLC19A1, LOC100129027, MCM3AP, YBEY and PRMT2 is also hyper-methylated in Down syndrome fetuses compared to normal fetuses or mothers.
[0019] The term "hyper-methylation" may refer to a state in which the methylation level of an experimental group is higher than that of a control group.
[0020] The methylation level of any one gene selected from the group consisting of IGHMBP2, MRGPRD and ITSN1 is also hypomethylated in Down syndrome fetuses compared to normal fetuses or mothers.
[0021] The term "hypo-methylation" may refer to a state in which the methylation level of an experimental group is lower than that of a control group.
[0022] The term "MXRA8" gene as used herein refers to a gene encoding matrix remodeling associated 8 protein. The gene or the protein encoded thereby has been known as a biomarker for diagnosing non-muscle invasive bladder cancer (Korean Patent Publication No. 10-2019-0089552).
[0023] The term "MIB2" gene as used herein refers to a gene encoding E3 ubiquitin-protein ligase 2 (MIB2). The protein MIB2 encoded by the gene is known to interact with actin protein (alpha 1) and suppress melanoma invasion.
[0024] The term "KIF26B" gene as used herein refers to a gene encoding the kinesin family member 26B (KIF26B) protein. The protein encoded by the gene is an intracellular motor protein that transports organelles along microtubules and is essential for kidney development, and elevated levels of the protein have been observed in some breast and colon cancers.
[0025] As used herein, the term "SP5" gene refers to a gene encoding the Sp5 transcription factor, which is known to be involved in Wnt-mediated beta-catenin signaling and the regulation of target gene transcription.
[0026] The term "ZIC4" gene in the present specification refers to a gene encoding Zic family member 4 (ZIC4) protein, specifically, a member protein of the Zic family of C2H2-type zinc finger proteins. The protein encoded by the gene is known to be associated with X-linked visceral heterotaxy and holoprosencephaly type 5.
[0027] As used herein, the term "ENPEP" gene refers to a gene encoding glutamyl aminopeptidase, which is known to be associated with choriocarcinoma and gestational choriocarcinoma.
[0028] The term "PITX2" gene as used herein refers to a gene encoding a protein also known as paired-like homeodomain transcription factor 2 or pituitary homeobox 2. Mutations in the gene are known to be associated with Axenfeld-Rieger syndrome and iridogoniodysgenesis syndrome.
[0029] As used herein, the term "SH3BP2" gene refers to a gene encoding SH3 domain-binding protein 2 (SH3BP2) derived from a gene located on chromosome 4. The protein encoded by the gene is known to be associated with cherubism.
[0030] As used herein, the term "SEPP1" gene refers to a gene encoding selenoprotein P. Selenoproteins are extracellular glycoproteins that are unusual in that they contain nine Sec residues per polypeptide and are known to act as antioxidants in the extracellular space.
[0031] The "FLJ32255" gene as used herein is an uncharacterized LOC643977 RNA gene related to the IncRNA class.
[0032] The term "SHROOM1" gene in this specification refers to the gene encoding the protein SHROOM1 family member 1, SHROOM1, which plays an important role in the development of the nervous system and different tissues, and is involved in the formation of microtubules during cell elongation. It is involved in congenital heart defects and arthritis in the condition of Down's syndrome.
[0033] The term "LINC00574" gene as used herein refers to long intergenic non-protein coding RNA 574, an RNA gene related to the IncRNA class. The LINC00574 gene is known to be associated with breast cancer.
[0034] The term "LOC154449" gene as used herein refers to uncharacterized LOC154449, an RNA gene related to the IncRNA class.
[0035] As used herein, the term "PRRT4" gene refers to a gene encoding proline rich transmembrane protein 4 (PRRT4), which is known to be associated with Zellweger syndrome.
[0036] The term "TMEM176B" gene as used herein refers to a gene encoding transmembrane protein 176B (TMEM176B), which is known to be involved in the maturation process of dendritic cells.
[0037] As used herein, the term "MNX1" gene refers to the gene encoding the protein also known as motor neuron and pancreas homeobox 1 (MNX1) protein or homeobox HB9 (HLXB9), mutations in which are known to be associated with Currarino syndrome.
[0038] The term "LOC101928483" gene as used herein is a non-coding RNA (ncRNA) and is also referred to as the NALT1 (NOTCH1 associated lncRNA in T cell acute lymphoblastic leukemia 1) gene.
[0039] The term "EGFL7" gene as used herein refers to a gene encoding EGF-like domain-containing protein 7. The expression of the gene is known to be abnormally expressed by tumor cells in human cancers and in endothelial cell-specific manner under physiological conditions.
[0040] The term "NACC2" gene as used herein refers to a gene encoding the NACC family member 2 protein, the protein encoded by which is known to be associated with lateral myocardial infarction and interstitial myocarditis.
[0041] The term "C9orf69" gene as used herein refers to a gene encoding transmembrane 250, also known as TMEM250. The protein encoded by the gene is known to promote progression to the S phase in the cell cycle and play an important role in cell proliferation.
[0042] The term "TLX1" gene as used herein refers to a gene encoding T-cell leukemia homeobox protein 1 (TLX1), also known as HOX11. The protein encoded by the gene is known to interact with PPP1CC (serine / threonine-protein phosphatase PP1-gamma catalytic subunit), PPP2CB (serine / threonine-protein phosphatase 2A catalytic subunit beta isoform), and PPP2CA (serine / threonine-protein phosphatase 2A catalytic subunit alpha isoform).
[0043] The term "FGF8" gene as used herein refers to a gene encoding fibroblast growth factor 8 (FGF8) protein. The protein encoded by the gene supports the androgen- and anchorage-independent growth of breast tumor cells, and overexpression of the gene is known to increase tumor growth and angiogenesis.
[0044] As used herein, the term "TACC2" gene refers to a gene encoding transforming acidic coiled-coil-containing protein 2 (TACC2). The gene encodes a protein that is concentrated at the centrosome throughout the cell cycle, and the gene resides in a chromosomal region associated with tumorigenesis. Expression of the gene is known to affect breast tumor progression.
[0045] As used herein, the term "CPXM2" gene refers to a gene encoding the carboxypeptidase X, M14 family member 2 (CPXM2) protein.
[0046] The term "NKX6-2" gene as used herein refers to a gene encoding the NK6 homeobox 2 (NKX6-2) protein, the protein encoded by which is known to be associated with spastic ataxia and autosomal recessive disorders.
[0047] The term "TLX1NB" gene as used herein refers to the TLX1 neighbor RNA gene and belongs to the IncRNA class.
[0048] The term "IQSEC3" gene in this specification refers to a human gene known as IQ motif and Sec7 domain 3, also called KIAA1110. The gene is highly expressed in the brain, particularly in the amygdala, and is known to play an important role in learning.
[0049] As used herein, the term "PCDH8" gene refers to a gene encoding the protocadherin-8 (PCDH8) protein, which encodes an integral membrane protein that appears to function in cell adhesion in a CNS-specific manner.
[0050] As used herein, the term "F7" gene refers to a gene encoding coagulation factor VII, a vitamin K-dependent factor essential for hemostasis, which is known to be associated with factor VII deficiency and myocardial infarction.
[0051] As used herein, the term "SOX9" gene refers to a gene encoding the transcription factor SOX-9 protein, mutations of which are known to be associated with skeletal malformation syndrome and campomelic dysplasia.
[0052] The term "PNMAL2" gene in this specification refers to a gene encoding the PNMA family member 8B (PNMA8B) protein, the important paralog of which is PNMA8A. The protein encoded by the gene refers to paraneoplastic antigen-like protein 8B.
[0053] The term "THBD" gene as used herein refers to a gene encoding thrombomodulin protein, which is a protein derived from endothelial cells of blood vessels and acts in conjunction with other factors to prevent the formation of intravascular thrombus.
[0054] The term "MAPK8IP2" gene in this specification means a gene encoding C-jun-amino-terminal kinase-interacting protein 2, also called IB2 (islet-brain-2). The protein encoded by said gene is highly expressed in the brain and is known to be almost always deleted in Phelan-McDermid syndrome.
[0055] As used herein, the term "KLHDC7B" gene refers to a gene encoding the Kelch domain containing 7B protein, which is known to be associated with chlamydia pneumonia.
[0056] As used herein, the term "GPR143" gene refers to a gene encoding the G-protein coupled receptor 143 protein, which is known to be regulated by microphthalmia-associated transcription factors.
[0057] As used herein, the term "IGHMBP2" gene refers to a gene encoding a protein known as immunoglobulin helicase μ-binding protein 2 (IGHMBP2), cardiac transcription factor 1 (CATF1), or DNA-binding protein SMUBP-2. Mutations in the gene are known to induce distal spinal muscular atrophy type 1.
[0058] As used herein, the term "MRGPRD" gene refers to a gene encoding the Mas-related G-protein coupled receptor member D protein, which is known to be associated with femoral cancer and liver rhabdomyosarcoma.
[0059] As used herein, the term "CHODL" refers to a gene encoding the chondrolectin protein. The exact function of the protein encoded by this gene is unknown, but it has been shown to be a marker of fast motor neurons in mice.
[0060] As used herein, the term "NCAM2" gene refers to a gene encoding the neural cell adhesion molecule 2 protein, which is known to be associated with prion diseases.
[0061] The term "CYYR1" gene as used herein refers to a gene encoding cysteine and tyrosine-rich protein 1 (CYYR1). The function of the protein encoded by the gene is not specifically known.
[0062] As used herein, the term "GRIK1" gene refers to a gene encoding the glutamate receptor, ionotropic, kainate 1 (GRIK1) protein, which encodes one of many ionotropic glutamate receptor (GluR) subunits that function as ligand-gated ion channels.
[0063] As used herein, the term "OLIG2" gene refers to a gene encoding the oligodendrocyte transcription factor protein, the expression of which is primarily restricted to the central nervous system, where it acts as both an anti-neurogenic and pro-neurogenic factor during different stages of development, and which is primarily known to be associated with brain tumors.
[0064] As used herein, the term "CLIC6" gene refers to the gene encoding chloride intracellular channel protein 6, which is known to interact with the dopamine receptor D3.
[0065] As used herein, the term "SIM2" gene refers to a gene encoding single-minded homolog 2 protein. The protein encoded by this gene is known to play an important role in the development of the central nervous system midline as well as the structure of the face and head.
[0066] As used herein, the term "HLCS" gene refers to a gene encoding a holocarboxylase synthetase protein. The protein encoded by this gene plays an important role in the efficient use of vitamin B (biotin), which is found in foods such as egg yolks and milk, and is known to be involved in many important cellular functions, including the production and breakdown of proteins, fats, and carbohydrates.
[0067] As used herein, the term "MX2" gene refers to a gene encoding interferon-induced GTP-binding protein Mx2, a protein encoded by said gene that is upregulated by interferon-alpha but does not contain the antiviral activity of the similar myxovirus resistance protein 1.
[0068] The term "MX1" gene in this specification refers to a gene encoding interferon-induced GTP-binding protein Mx1. Interferon-induced Mx protein in mice is known to be associated with a specific antiviral state against influenza virus infection.
[0069] The term "TMPRSS2" gene in this specification refers to a gene encoding a transmembrane protease, serine 2 protein. Serine proteases are known to be involved in many physiological and pathological processes, and the gene is known to be upregulated by androgen hormone in prostate cancer cells and downregulated in androgen-independent prostate cancer tissues. However, the specific biological function of the gene is unknown.
[0070] The term "SLC37A1" gene in this specification refers to a gene encoding the glucose-6-phosphate exchanger SLC37A1 protein. Unlike the SLC37A4 protein, the protein encoded by said gene does not appear to be involved in blood glucose homeostasis, but is known to regulate phosphate levels in milk of dairy cows and affect the amount of milk produced.
[0071] The term "PDE9A" gene as used herein refers to a gene encoding high affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A protein. The protein encoded by the gene is known to play a role in signal transduction by regulating the intracellular concentrations of cAMP and cGMP.
[0072] The term "CBS" gene as used herein refers to a gene encoding cystathionine beta-synthase, the defect of which is known to cause cystathionine beta-synthase deficiency (CBSD) and homocystinuria.
[0073] As used herein, the term "CRYAA" gene refers to a gene encoding the alpha-crystallin A chain protein, defects of which are known to cause autosomal dominant congenital cataract.
[0074] As used herein, the term "C21orf2" gene refers to a gene encoding cilia and flagella associated protein 410 (CFAP410), which is known to be associated with retinal dystrophy and spondylometaphyseal dysplasia.
[0075] As used herein, the term "TRPM2" gene refers to a gene encoding a protein of the transient receptor potential cation channel, subfamily M, member 2. The physiological function of the gene is not precisely known, but it has been reported to be involved in insulin secretion.
[0076] As used herein, the term "TSPEAR" gene refers to a gene encoding a thrombospondin type laminin G domain and EAR repeats protein, which is known to be associated with deafness and ectodermal dysplasia.
[0077] The term "LINC00162" gene in this specification refers to the P38 inhibited cutaneous squamous cell carcinoma associated LincRNA (PICSAR) gene, which is known to be associated with narcolepsy and embryonal testis carcinoma.
[0078] The term "SSR4P1" gene in this specification refers to signal sequence receptor subunit 4P pseudogene 1. The exact function of the gene is not known.
[0079] As used herein, the term "SLC19A1" gene refers to a gene encoding folate transporter 1 protein. The protein encoded by the gene is known to play an important role in maintaining intracellular folate concentration.
[0080] The term "LOC100129027" gene in this specification refers to the PCBP3 antisense RNA1 (PCBP3-AS1) gene. The specific biological function of said gene is not known.
[0081] The term "MCM3AP" gene as used herein refers to a protein encoding the 80 kDa MCM3-associated protein. The protein encoded by the gene is an MCM3-binding protein, which is known to have phosphorylation-dependent DNA primase activity.
[0082] As used herein, the term "YBEY" gene refers to a gene encoding YbeY metalloendoribonuclease, which is known to be associated with mesenteric lymphadenitis.
[0083] As used herein, the term "PRMT2" gene refers to a gene encoding protein arginine N-methyltransferase 2. The protein encoded by the gene is known to interact with estrogen receptor alpha.
[0084] As used herein, the term "ITSN1" gene refers to a gene encoding the intersectin-1 protein, which is known to be associated with vaccinia and schizophrenia 1.
[0085] In another aspect, a kit for diagnosing Down's syndrome is provided, which comprises the composition for diagnosing Down's syndrome.
[0086] The kit may be any one selected from the group consisting of an RT-PCR kit, a microarray chip kit, and a DNA kit.
[0087] The microarray may refer to either a "DNA microarray" or a "DNA chip" as broadly recognized in the art, and may include any solid support known in the art, and may refer to any method for attaching a nucleic acid molecule thereto or synthesizing a nucleic acid thereon.
[0088] In another embodiment, the kit is a kit including essential elements required for carrying out a microarray. The microarray kit includes a substrate to which a gene or a cDNA corresponding to a fragment thereof is attached as a probe, and the substrate includes a quantitative control gene or a cDNA corresponding to a fragment thereof, and is easily manufactured by a manufacturing method generally used in the art using the gene. To prepare the microarray, a probe DNA molecule is used to immobilize the probed marker on the substrate of the DNA chip, and a micropipetting method using a piezoelectric method or a method using a pin-shaped spotter can be used. The substrate of the microarray chip is coated with an active group selected from the group consisting of amino-silane, poly-L-lysine, and aldehyde. The substrate can also be selected from the group consisting of slide glass, plastic, metal, silicon, nylon membrane, and nitrocellulose membrane.
[0089] Yet another embodiment is directed to (a) detecting from a biological sample isolated from a fetus, among others, MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ32255, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, LOC101928483, EGFL7, NACC2, C9orf69, TLX1, FGF8, TACC2, CPXM2, NKX6-2, TLX1NB, IQSEC3, PCDH8, F7, SOX9, PNMAL2, THBD, MAPK8IP2, KLHDC7B, GPR143, IGHMBP2, MRG The present invention provides a method for diagnosing Down's syndrome, comprising: (a) measuring a methylation level of any one gene selected from the group consisting of PRD, CHODL, NCAM2, CYYR1, GRIK1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, C21orf2, TRPM2, TSPEAR, LINC00162, SSR4P1, SLC19A1, LOC100129027, MCM3AP, YBEY, PRMT2, and ITSN1; and (b) comparing the measured methylation level with that of a normal control sample.
[0090] The term "biological sample" as used herein includes samples such as tissues, cells, whole blood, serum, plasma, saliva, sputum, cerebrospinal fluid, urine, isolated from a fetus outside the body, and also includes cell-free DNA, which is DNA that is not present in a cell nucleus and is released into the blood.
[0091] The biological sample may also be derived from the placenta. The term "placenta" refers to a structure that mediates the exchange of substances between the fetus and the mother, which is necessary for the growth and survival of the fetus, and is formed when a part of the intestinal membrane that surrounds the fetus from the outside adheres to the endometrium of the mother. The placenta may also include the chorion. The term "chorion" refers to the middle layer of the decidua, chorion, and amnion, which are membranes that surround the amniotic fluid in the uterus. The chorion is generated from a fertilized egg, constitutes a part of the egg membrane, and is densely covered with numerous protrusions, called chorionic villi, on the front side, which play a role in penetrating the fertilized egg into the inner wall of the uterus. For example, the biological sample may also be derived from chorionic villus cells. Preferably, it may refer to cell-free DNA in maternal blood derived from the chorionic villus cells.
[0092] The term "fetus" in this specification refers to a fetus for which the onset of Down's syndrome is confirmed or the risk of onset of Down's syndrome is predicted. The fetus is not limited to any particular species, so long as it is an animal capable of developing Down's syndrome, and specifically may be a mammal, such as a human (Homo sapiens).
[0093] The method further comprises the step (b) of measuring MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ32255, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, LOC101928483, EGFL7, NACC2, C9orf69, TLX1, FGF8, TACC2, CPXM2, NKX6-2, TLX1NB, IQSEC3, PCDH8, F7, SOX9, PNMAL2, TH The method further includes a step of determining that the patient has Down's syndrome when the methylation level of any one gene selected from the group consisting of BD, MAPK8IP2, KLHDC7B, GPR143, CHODL, NCAM2, CYYR1, GRIK1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, C21orf2, TRPM2, TSPEAR, LINC00162, SSR4P1, SLC19A1, LOC100129027, MCM3AP, YBEY, and PRMT2 is elevated compared to a normal control group.
[0094] The method may further include a step of determining that the patient has Down syndrome if the methylation level of the IGHMBP2 gene, the MGRPRD gene, or the ISTN1 gene measured in a biological sample isolated from the fetus in step (b) is reduced compared to a normal control group.
[0095] The method for measuring the methylation level may be selected from the group consisting of PCR, methylation specific PCR, real time methylation specific PCR, PCR using a methylated DNA specific binding protein, quantitative PCR, PCR using a methylation specific PNA, melting curve analysis, DNA chip, pyrosequencing, bisulfite sequencing, and methyl-capture sequencing (MC-Seq).
[0096] The method also includes comparing the measured methylation level to that of a normal control sample. If the methylation level in the sample is higher or lower than that of the normal control sample, the fetus can be determined to have or be likely to have Down's syndrome. The change in methylation level also includes a similar level or an increase of 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900% and 1000% or more in the fetal methylation level compared to the normal or negative control.
[0097] In one embodiment, it was confirmed that the Down's syndrome diagnostic biomarker genes can detect on-off forms of Down's syndrome through differences in methylation levels. Specifically, the DNA methylation levels of CHODL, NCAM2, CYYR1, GRIK1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, C21orf2, TRPM2, TSPEAR, LINC00162, SSR4P1, SLC19A1, LOC100129027, MCM3AP, YBEY, PRMT2, and ITSN1, which are Down's syndrome specific biomarkers present on chromosome 21, were measured, and it was confirmed that there was a 10% or more difference in methylation levels between normal maternal blood and normal fetal placenta in a tissue-specific manner, and that there was a 10% or more difference in methylation levels between normal fetal placenta and Down's syndrome fetal placenta in a disease-specific manner.
[0098] In addition, Down syndrome-specific biomarkers present on other chromosomes except chromosome 21, including MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ32255, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, LOC101928483, EGFL7, NACC2, C9orf69, TLX1, FGF8, TACC2, and CP We measured the DNA methylation levels of XM2, NKX6-2, TLX1NB, IQSEC3, PCDH8, F7, SOX9, PNMAL2, THBD, MAPK8IP2, KLHDC7B, GPR143, IGHMBP2 and MRGPRD and found that there was a tissue-specific difference in methylation levels of more than 10% between normal maternal blood and normal fetal placenta, and a disease-specific difference in methylation levels of more than 30% between normal fetal placenta and Down syndrome fetal placenta.
[0099] Yet another embodiment is directed to (a) detecting from a biological sample isolated from a fetus, one or more of the following: MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ32255, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, LOC101928483, EGFL7, NACC2, C9orf69, TLX1, FGF8, TACC2, CPXM2, NKX6-2, TLX1NB, IQSEC3, PCDH8, F7, SOX9, PNMAL2, THBD, MAPK8IP2, KLHDC7B, GPR143, IGHMBP2, MRGPRD, The present invention provides a method for providing information for diagnosing Down's syndrome, comprising: (a) measuring the methylation level of any one gene selected from the group consisting of CHODL, NCAM2, CYYR1, GRIK1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, C21orf2, TRPM2, TSPEAR, LINC00162, SSR4P1, SLC19A1, LOC100129027, MCM3AP, YBEY, PRMT2, and ITSN1; and (b) comparing the measured methylation level with that of a normal control sample.
[0100] The other details relating to the biological samples, fetus, stage (a) and stage (b) are as set forth above.
[0101] Yet other embodiments include the use of MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ32255, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, LOC101928483, EGFL7, NACC2, C9orf69, TLX1, FGF8, TACC2, CPXM2, NKX6-2, TLX1NB, IQSEC3, PCDH8, F7, SOX9, PNMAL2, THBD, MAPK8IP2, KLHDC7B for Down Syndrome diagnosis. The present invention provides use of a composition comprising a preparation for measuring the methylation level of any one gene selected from the group consisting of: GPR143, IGHMBP2, MRGPRD, CHODL, NCAM2, CYYR1, GRIK1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, C21orf2, TRPM2, TSPEAR, LINC00162, SSR4P1, SLC19A1, LOC100129027, MCM3AP, YBEY, PRMT2 and ITSN1.
[0102] The details regarding the gene and the preparation for measuring the methylation level are as described above. Effect of the Invention
[0103] MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ32255, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, LOC101928483, EGFL7, NACC2, C 9orf69, TLX1, FGF8, TACC2, CPXM2, NKX6-2, TLX1NB, IQSEC3, PCDH8, F7, SOX9, PNMAL2, THBD, MAPK8IP2, KLHDC7B, GPR143, IGHMBP2, MRGPRD, CHODL, NCAM2, CYYR1, GRI A composition for diagnosing Down's syndrome comprising a preparation for measuring the methylation level of any one gene selected from the group consisting of K1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, C21orf2, TRPM2, TSPEAR, LINC00162, SSR4P1, SLC19A1, LOC100129027, MCM3AP, YBEY, PRMT2 and ITSN1, and a kit and method for diagnosing Down's syndrome comprising the same have the effect of enabling Down's syndrome to be diagnosed more simply and accurately. [Brief description of the drawings]
[0104] [Figure 1] The results are a comparison of the mean methylation levels of 65 biomarkers between groups based on analysis of methylation levels of chromosome 21 in normal maternal blood (NB), normal fetal placental tissue (NT), and Down syndrome fetal placental tissue (T21T). [Diagram 2] The results are a comparison of the methylation levels of 33 biomarkers between groups through analysis of gene methylation levels in normal maternal blood (NB), normal fetal placental tissue (NT), and Down syndrome fetal placental tissue (T21T). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0105] The present invention will be described in more detail below through examples. However, these examples are for illustrative purposes only and the scope of the present invention is not limited to these examples.
[0106] Example 1: DNA isolation in maternal blood and placental tissue The study was conducted under the approval of the Institutional Review Board of Daiichi Hospital (#CGH-IRB-2016-5). This study was conducted on singleton pregnant women who underwent obstetric and gynecological care at the Obstetrics and Gynecology Department of Daiichi Hospital from June 2015 to May 2017. Written informed consent was obtained from all patients, which was approved by the IRB. Placental tissues were chorionic villus cells used for chorionic villus sampling, which were collected early in pregnancy (12-13 weeks) and stored in liquid nitrogen until analysis. The gestational age of each fetus was determined by ultrasound examination. Chromosome analysis was performed using the GTG banding method to determine the karyotype of fetal chorionic villus cells. All placental tissues from the Down syndrome (DS) group had a complete extra copy of HSA21 (47,XX,+21 or 47,XY,+21), and all placental tissues from the control group (N(normal)) showed normal karyotype (46,XX or 46,XY). Fetal sex ratios were matched between the experimental group (Down syndrome fetus group) and the control group (normal fetus group). Genomic DNA for each sample was extracted from chorionic villus cells using the QIAamp DNA Mini Kit (catalog no. 51304 (Qiagen)) according to the manufacturer's instructions. Maternal blood was collected prior to chorionic villus sampling and genomic DNA was immediately extracted using the QIAamp DNA Mini Kit (catalog no. 51304 (Qiagen)) according to the manufacturer's instructions and stored in an ultra-low temperature freezer until analysis.
[0107] As shown in Table 1 below, there were no significant differences between the experimental and control groups in terms of maternal age, gestational age, translucency, and fetal sex ratio in the collection of chorionic villus cells (P>0.05).
[0108] [Table 1]
[0109] Example 2: Highly efficient methylome profiling using MC-seq Based on the DNA samples of normal maternal blood, normal fetal placental tissue, and Down syndrome fetal placental tissue collected in Example 1, MC-seq was used to quantify DNA methylation at various CpG sites and perform methylome profiling.
[0110] Standard DNA methylation capture libraries were generated using the SureSelect Methyl-Seq Target Enrichment protocol (Agilent) for paired-end sequencing libraries (ver. B.3, June 2015 (Illumina)) with 3 μg genomic DNA. The SureSelect Human Methyl-Seq probe set (catalog number 5190-4662 (Agilent)) was used. DNA quantification and DNA quality were performed using a PicoGreen analysis kit (catalog number P7589 (Thermo Fisher Scientific)) and a NanoDrop spectrophotometer (catalog number ND-2000 (NanoDrop Technologies)), respectively. Three μg of genome was fragmented to a target size of 150-200 bp DNA using an ultrasonic disrupter (AFA (catalog number 500219) (Covaris)). Briefly, eight microtube strips were loaded into the tube holder of the sonicator and DNA was sheared using the following settings (mode: frequency sweeping; duty cycle: 10%; intensity: 5; number of cycles per burst: 200; duration: 60 s x 6 cycles; temperature: 4 °C - 7 °C). The fragmented DNA was repaired, an "A" was ligated to the 3' end, and a SureSelect Methyl-Seq Methylated Adapter was ligated to the fragment. Once ligation was assessed, the adapter-ligated product was amplified by PCR.
[0111] The final purified products, such as methylated adaptor-ligated DNA, were then quantified by qPCR quantification protocol guide and verified using TapeStation DNA Screen Tape D1000 (Cat. No. 5067-5582 (Agilent)). For DNA methylation region capture, 350ng of DNA library was mixed with hybridization buffer, blocking mix, RNase block, and 5μl of SureSelect All DNA methylation region capture library by standard SureSelect Methyl-Seq Target Enrichment protocol (Agilent). Hybridization to capture bait was performed at 65°C using a PCR machine with the thermocycler read option heated at 105°C for 24 hours. Target captured DNA was treated with bisulfite using EZDNA Methylation Gold Kit (Cat. No. D5005 (Zymo Research)) and subjected to 8 PCR cycles to enrich adaptor-ligated fragments and 6 PCR cycles to add multiplexed barcodes. The captured DNA was amplified. The final purified product was quantified using the qPCR quantification protocol guide described above and verified using a TapeStation DNA Screen Tape D1000 (Cat. No. 5067-582 (Agilent)). Sequencing was performed using a HiSeq™ 2500 platform (Cat. No. SY-401-2501 (Illumina)).
[0112] Example 3: Data processing and methylation profiles Data processing and methylation profile analysis were performed on the final product methylated in Example 2.
[0113] The quality of the paired end raw reads generated by sequencing was checked using FastQC software (version 0.11.5). Before starting the analysis, adaptor sequences and bases with a base quality of 3 or less were removed from the final data using Trimmomatic (version 0.32). A sliding window trim method was also used to remove bases that did not meet the following criteria: window size = 4, mean quality = 15. To generate cleaned data, data with a minimum length of 36 bp were removed. The cleaned reads were aligned to the Homo sapiens genome (UCSC hg19) using the Bisulfite Sequencing MAPping program based on Unidirectional Oligo Alignment Program (SOAP) (version 2.90 (parameter set-n1-r0) (BSMAP)), which was uniquely mapped to the data. The mapped data in SAM file format were aligned and indexed using SAMtools (version 1.2). PCR duplicates were excluded with Sambamba (version 0.5.9). Methylation levels were measured with the methratio.py feature in the BSMAP program. A methylation ratio higher than 10 CT numbers of all single cytosines located in the Agilent SureSelect target region could be considered as a general methylation completion. In the case of regions covered at both ends of a read pair, only one read was used to call methylation. The result coverage profile was summarized as follows: # of C / actual CT number for each of the three sequence contexts (CG, CHG and CHH).
[0114] After interpreting the methylation levels, the methylation levels at each base of CpGs were normalized by mean scaling normalization to distinguish DMCs from DMRs. For five comparison pairs, an independent T-test was used to evaluate the significance of the methylation difference between two groups. P values were corrected using the Benjamini-Hochberg FDR (false discovery rate) method to control for false positive results in the various tests. Principal component analysis showed separation of samples based on disease status (normal or DS) but not on fetal sex, as in previous studies. DMCs were determined by filtering each region with |delta_mean| ≥ 0.1, independent T-test p value < 0.05, and FDR < 0.05. DMRs were defined as contiguous regions of any length that contained ≥ 3 DMCs. Hierarchical clustering analysis was further performed using complete linkage and Euclidean distance as measures of similarity to display the methylation levels of samples with significant CpGs that satisfied one or more comparison pairs. Heatmaps were automatically floated by central linkage using central absolute correlation as the similarity metric. All data analysis and visualization of differentially methylated results were performed using R 3.3.1 (www.r-project.org) and Statistical Package for Social Sciences 12.0 (SPSS Inc.).
[0115] Example 4: Discovery of specific epigenetic markers in the placenta of Down's syndrome fetuses Using five samples each of the blood of mothers with normal fetuses, the placenta of normal fetuses, and the placenta of Down's syndrome fetuses obtained in Example 1, gene methylation patterns were comparatively analyzed at the CpG site level using the method disclosed in Example 2. In this case, the methylation level (%) of each CpG site was expressed as 0 to 100, with 0 meaning unmethylated and 100 meaning complete methylation. Depending on the difference in the comparatively analyzed methylation levels, biomarkers that are hypermethylated or hypomethylated were discovered.
[0116] 4-1. Comparison of methylation levels on chromosome 21 Based on chromosome 21, the target chromosome for Down syndrome, the following gene regions were selected as sites with three or more consecutive identical epigenetic traits: CHODL, NCAM2, CYYR1, GRIK1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, TRPM2, C21orf2, TSPEAR, LINC00162, SSR4P1, SLC19A1, LOC100129027, MCM3AP, YBEY, PRMT2, and ITSN1. Specific information on the selected 65 gene regions is shown in Table 2 below.
[0117] [Table 2-1] [Table 2-2]
[0118] The methylation levels (methylation level (%) divided by 100) of the above-selected gene regions in normal maternal blood, normal fetal placenta, and Down's syndrome fetal placenta are shown in Table 3 below and FIG. 1.
[0119] [Table 3-1] [Table 3-2]
[0120] The differences in methylation levels between normal fetal placenta and maternal blood cells, and between Down syndrome fetal placenta and normal fetal placenta were compared.
[0121] As a result, as shown in Table 3 and Figure 1, it was confirmed that the gene regions of CHODL, NCAM2, CYYR1, GRIK1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, TRPM2, C21orf2, TSPEAR, SSR4P1, LINC00162, MCM3AP, YBEY and PRMT2(NONE) are hypermethylated in the fetal placenta, particularly in the placenta of a Down's syndrome fetus. Specifically, the difference in methylation level of the above-mentioned genes between normal fetal placenta and maternal blood cells was 10 to 55, and it was confirmed that the genes are hypermethylated in the fetal placenta compared to maternal blood, and are tissue (placenta) specific biomarkers. In addition, the difference in methylation levels of the aforementioned genes between Down's syndrome fetal placenta and normal fetal placenta was 10 to 20, confirming that they are disease (Down's syndrome)-specific biomarkers that are hypermethylated in Down's syndrome fetuses compared to normal fetuses. The difference in methylation levels between Down's syndrome fetal placenta and the other two groups (normal fetal placenta and maternal blood) was both statistically significant (P<0.05).
[0122] We also confirmed that the ITSN1 gene region is hypomethylated in the placenta of Down's syndrome fetuses. Specifically, the methylation level of the ITSN1 gene region in maternal blood cells was 90 or more, while the methylation level in normal fetal placenta was 65 or more, indicating hypermethylation, whereas the methylation level in Down's syndrome fetal placenta was 40 or less, indicating hypomethylation. The difference in methylation level between the groups was 25 or more. In this case, the difference in methylation level between Down's syndrome fetal placenta and the other two groups (normal fetal placenta and maternal blood) was statistically significant (P<0.05).
[0123] 4-2. Comparison of methylation levels in other chromosomes except for chromosome 21 The following gene regions were selected as sites with two or more consecutive identical epigenetic features: MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ32255, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, LOC101928483, EGFL7, NACC2, C9orf69, TLX1, FGF8, TACC2, CPXM2, NKX6-2, TLX1NB, IQSEC3, PCDH8, F7, SOX9, PNMAL2, THBD, MAPK8IP2, KLHDC7B, GPR143, IGHMBP2, and MRGPRD. The specific information of the selected 33 gene regions is shown in Table 4 below.
[0124] [Table 4]
[0125] The methylation levels (methylation level (%) divided by 100) of the above-selected gene regions in normal maternal blood, normal fetal placenta, and Down's syndrome fetal placenta are shown in Table 5 below and FIG. 2.
[0126] [Table 5]
[0127] The differences in methylation levels between normal fetal placenta and maternal blood cells, and between Down syndrome fetal placenta and normal fetal placenta were compared.
[0128] As a result, as shown in Table 5 and Figure 2, it was confirmed that the gene regions of MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ32255, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, EGFL7, LOC101928483, NACC2, C9orf69, TLX1, FGF8, TACC2, CPXM2, NKX6-2, TLX1NB, IQSEC3, PCDH8, F7, SOX9, PNMAL2, THBD, MAPK8IP2, KLHDC7B and GPR143 are hypermethylated in the fetal placenta, particularly in the placenta of a fetus with Down's syndrome. Specifically, the difference in methylation levels of the aforementioned genes between normal fetal placenta and maternal blood cells was 10 to 50, confirming that they are hypermethylated in fetal placenta compared to maternal blood and are tissue (placenta) specific biomarkers. In addition, the difference in methylation levels of the aforementioned genes between Down's syndrome fetal placenta and normal fetal placenta was 25 to 50, confirming that they are disease specific as hypermethylated biomarkers in Down's syndrome fetuses compared to normal fetuses. The difference in methylation levels between Down's syndrome fetal placenta and the other two groups (normal fetal placenta and maternal blood) was both statistically significant (P<0.05).
[0129] We also confirmed that the IGHMBP2 and MRGPRD gene regions were hypomethylated in the placenta of Down's syndrome fetuses. In normal fetal placenta and maternal blood cells, the methylation levels of the IGHMBP2 and MRGPRD gene regions were hypermethylated (75 or more), whereas in Down's syndrome fetal placenta, the methylation level was hypomethylated (15 or less). In both cases, the differences in methylation levels between Down's syndrome fetal placenta and the other two groups (normal fetal placenta and maternal blood) were statistically significant (P<0.05).
[0130] The results of Example 4 described above were summarized as follows: MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ32255, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, LOC101928483, EGFL7, NACC2, C9orf69, TLX1, FGF8, TACC2, CPXM2, NKX6-2, TLX1NB, IQSEC3, PCDH8, F7, SOX9, PNMAL2, THBD, MAPK8IP2, KLHDC7B, GPR143, IGHMB It has been confirmed that the genes P2, MRGPRD; and CHODL, NCAM2, CYYR1, GRIK1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, C21orf2, TRPM2, TSPEAR, LINC00162, SSR4P1, SLC19A1, LOC100129027, MCM3AP, YBEY, PRMT2, and ITSN1 in chromosome 21 can be biomarkers that show significant epigenetic characteristics in Down syndrome fetuses compared to mothers and normal fetuses.
[0131] Specifically, the DNA methylation level of the Down syndrome-specific biomarker present on chromosome 21 is "normal maternal blood: normal fetal placenta: Down syndrome fetal placenta = 0 to 10:20:40", and the difference in methylation level due to disease is approximately 20%. If the numerical increase rate of the target chromosome 21 (1.5 times) is reflected, it can be confirmed that the difference in methylation level is ultimately approximately 30%.
[0132] In addition, the DNA methylation levels of Down syndrome-specific biomarkers present on chromosomes other than chromosome 21 were "normal maternal blood: normal fetal placenta: Down syndrome fetal placenta = 0 to 10:30:70," and it was confirmed that the difference in the degree of methylation due to the disease was approximately 40%.
[0133] That is, through the above results, it is possible to confirm a specific standard for comparison with the DNA methylation level of the mother or normal fetus, by measuring the DNA methylation level of the biomarker gene, which can diagnose a fetus with Down's syndrome.
Claims
1. MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ3225 5, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, LOC1019284 83, EGFL7, NACC2, C9orf69, TLX1, FGF8, TACC2, CPXM2, NKX6-2, TLX1NB, I QSEC3, PCDH8, F7, SOX9, PNMAL2, THBD, MAPK8IP2, KLHDC7B, GPR143, IGHM A composition for diagnosing Down's syndrome, comprising a preparation for measuring the methylation level of any one gene selected from the group consisting of BP2, MRGPRD, CHODL, NCAM2, CYYR1, GRIK1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, C21orf2, TRPM2, TSPEAR, LINC00162, SSR4P1, SLC19A1, LOC100129027, MCM3AP, YBEY, PRMT2 and ITSN1.
2. The aforementioned MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ32255, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, LOC101928483, EGFL7, NACC2, C9orf69, TLX1, FGF The composition for diagnosing Down's syndrome according to claim 1, wherein the genes for chromosome 8, TACC2, CPXM2, NKX6-2, TLX1NB, IQSEC3, PCDH8, F7, SOX9, PNMAL2, THBD, MAPK8IP2, KLHDC7B, GPR143, IGHMBP2 and MRGPRD are present on chromosomes other than chromosome 21.
3. The composition for diagnosing Down's syndrome according to claim 1, wherein the above-mentioned CHODL, NCAM2, CYYR1, GRIK1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, C21orf2, TRPM2, TSPEAR, LINC00162, SSR4P1, SLC19A1, LOC100129027, MCM3AP, YBEY, PRMT2 and ITSN1 genes are present on chromosome 21.
4. The aforementioned MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ3225 5, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, LOC101928483, EGFL7, NACC2, C9orf69, TLX1, FGF8, TACC2, CPXM2, NKX6-2, TLX1NB, IQSEC3, PCDH8, F7, SOX9, PNMAL2, THBD, MAPK8IP2, KLHDC7B, GPR143, CHODL, NCAM2, C The composition for diagnosing Down's syndrome according to claim 1, wherein the methylation level of any one gene selected from the group consisting of YYR1, GRIK1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, C21orf2, TRPM2, TSPEAR, LINC00162, SSR4P1, SLC19A1, LOC100129027, MCM3AP, YBEY and PRMT2 is hypermethylated in a Down's syndrome fetus compared to a normal fetus or maternal blood.
5. The composition for diagnosing Down's syndrome according to claim 1, wherein the methylation level of any one of the genes selected from the group consisting of IGHMBP2, MRGPRD and ITSN1 is hypomethylated in a Down's syndrome fetus compared to normal fetus or maternal blood.
6. A kit for diagnosing Down's syndrome, comprising the composition according to any one of claims 1 to 5.
7. 7. The kit for diagnosing Down's syndrome according to claim 6, wherein the kit is any one selected from the group consisting of an RT-PCR kit, a microarray chip kit, and a DNA kit.
8. (a) From biological samples isolated from fetuses, the following genes were identified: MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ32255, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, LOC101928483, EGFL7, NACC2, C9orf69, TLX1, FGF8, TACC2, CPXM2, NKX6-2, TLX1NB, IQSEC3, PCDH8, F7, SOX9, PNMAL2, THBD, MAPKIP2, KIP1, and KIP2. measuring a methylation level of any one gene selected from the group consisting of LHDC7B, GPR143, IGHMBP2, MRGPRD, CHODL, NCAM2, CYYR1, GRIK1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, C21orf2, TRPM2, TSPEAR, LINC00162, SSR4P1, SLC19A1, LOC100129027, MCM3AP, YBEY, PRMT2, and ITSN1; (b) comparing the measured methylation levels with levels in a normal control sample.
9. 9. The method of claim 8, wherein the biological sample is derived from a placenta.
10. In the step (b), MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ32255, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, LOC101928483, EGFL7, NACC2, C9orf69, TLX1, FGF8, TACC2, CPXM2, NKX6-2, TLX1NB, IQSEC3, PCDH8, F7, SOX9, PNMAL2, THBD, MAPK8IP2, KLHDC7, 9. The method of claim 8, further comprising determining that the patient has Down's syndrome when a methylation level of any one gene selected from the group consisting of B, GPR143, CHODL, NCAM2, CYYR1, GRIK1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, C21orf2, TRPM2, TSPEAR, LINC00162, SSR4P1, SLC19A1, LOC100129027, MCM3AP, YBEY and PRMT2 is increased compared to a normal control group.
11. The method according to claim 8, further comprising a step of determining that the patient has Down's syndrome when the methylation level of any one gene selected from the group consisting of IGHMBP2, MRGPRD and ITSN1 measured in the biological sample isolated from the fetus is decreased compared to a normal control group in step (b).
12. 9. The method of claim 8, wherein the method for measuring the methylation level is selected from the group consisting of PCR, methylation specific PCR, real time methylation specific PCR, PCR using a methylated DNA specific binding protein, quantitative PCR, PCR using a methylation specific PNA, melting curve analysis, DNA chip, pyrosequencing, bisulfite sequencing, and methylation next generation base sequence sequencing.
